Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Lamivudine- and Adefovir-Induced Tinnitus in a Patient with Hepatitis B: A Case Report

B형 간염 환자에서 Lamivudine과 Adefovir 병용처방으로 유발된 이명의 증례보고

  • Jung, Eun-Hee (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Bang, Joon Seok (Department of Clinical Pharmacy, College of Pharmacy, Chosun University) ;
  • Lee, Yu Jeung (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University)
  • 정은희 (숙명여자대학교 임상약학대학원) ;
  • 방준석 (조선대학교 약학대학) ;
  • 이유정 (강원대학교 약학대학)
  • Received : 2013.04.14
  • Accepted : 2013.05.22
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Lamivudine and adefovir are medications used to treat hepatitis B. We observed the occurrence of tinnitus after administering lamivudine and adefovir to a 49-year-old hepatitis B patient for two months. The patient had no comorbidities and no history of ear diseases, including tinnitus, and was not taking any other medications. In general, neither lamivudine nor adefovir are known to induce tinnitus as an adverse reaction. A literature search revealed that this is the first case in which tinnitus occurred after lamivudine and adefovir were administered to a hepatitis B patient. Therefore, we believe that this case is clinically valuable and decided to report it.

Keywords

References

  1. Pluda JM, Cooley TP, Montaner JS, et al., A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171: 1438-47. https://doi.org/10.1093/infdis/171.6.1438
  2. Nevens F, Main J, Honkoop P, et al., Lamivudine therapy for chronic hepatitis B: a six-month randomized doseranging study. Gastroenterology 1997; 113: 1258-63. https://doi.org/10.1053/gast.1997.v113.pm9322520
  3. Perry CM, Faulds D, Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53: 657-80 https://doi.org/10.2165/00003495-199753040-00008
  4. Fung J, Lai CL, Seto WK, et al., Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66: 2715-25. https://doi.org/10.1093/jac/dkr388
  5. Jayasekara D, Aweeka FT, Rodriguez R, et al., Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr 1999; 21: 384-95. https://doi.org/10.1097/00126334-199908150-00005
  6. GlaxoSmithKline. Epivir-HBV(R) (lamivudine) tablets and oral solution prescribing information. Research Triangle Park, NC 2007.
  7. Carr A, Cooper DA, Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30. https://doi.org/10.1016/S0140-6736(00)02854-3
  8. Cundy KC, Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36: 127-43. https://doi.org/10.2165/00003088-199936020-00004
  9. De Clercq E, Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16: 569-96. https://doi.org/10.1128/CMR.16.4.569-596.2003
  10. Gilead Sciences, Inc. Hepsera(R) (adefovir dipivoxil) tablet prescribing information. Foster City, CA 2008.
  11. Simdon J, Watters D, Bartlett S, et al., Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis 2001; 32: 1623-7. https://doi.org/10.1086/320522
  12. Eser Karlidag G, Karlidag T, Demirdag K, et al., The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B. Auris Nasus Larynx 2011; 38: 312-8. https://doi.org/10.1016/j.anl.2010.10.007